Sight Sciences : Investor Presentation - Nov 23

Investor Presentation

November 2023

Forward-Looking Statements

This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact, including statements regarding our future results of operations, product development, market opportunity, clinical trial results and timeline, and business strategy and plans. The forward-looking statements in this presentation include, but are not limited to, statements concerning the following: the Company's mission; the Company's projected financial or operational results; estimates of the Company's addressable markets for its products; the Company's ability to gain share in existing markets and enter into and compete in new markets; the Company's ability to successfully develop and commercialize its product pipeline; the Company's ability to compete effectively; the Company's ability to manage and grow its business; the Company's ability to successfully execute its clinical trial roadmap; the Company's ability to successfully execute its strategic initiatives and objectives; and the Company's ability to obtain and maintain sufficient reimbursement for its products. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. Management bases these forward-looking statements on its current expectations, plans and assumptions affecting the Company's business and industry, and such statements are based on information available as of the time such statements are made. Although management believes these forward- looking statements are based upon reasonable assumptions, it cannot guarantee their accuracy or completeness. Forward-looking statements are subject to and involve risks, uncertainties and assumptions that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance, or achievements predicted, assumed or implied by such forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the caption "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, as such may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source.

The Company has proprietary rights to trademarks, trade names and service marks appearing in this presentation that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this presentation without the ® and ™ symbols, but any such references are not intended to indicate that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. The Company does not intend its use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of the Company by, these other parties. Without limitation, SIGHT SCIENCES™, SIGHT SCIENCES (with design)®, OMNI®, SION™, TEARCARE® , SMARTLIDS™ and DELIVERING THE POWER OF SIGHT ™ are trademarks of Sight Sciences, Inc. in the United States and other countries. RESTASIS® is a registered trademark of Allergan, Inc., and IRIS® is a registered trademark of the American Academy of Ophthalmology.

2

Our Mission

Transform treatment of Eye Diseases by treating underlying causes

Earlier intervention helps restore the natural functionality of healthy eyes thereby improving long-term outcomes

Eyecare Innovation in

Glaucoma and Dry Eye

Large + Underserved Markets

Glaucoma

$6 billion addressable market1

3.4 million US patients diagnosed with Primary Open-Angle Glaucoma2

Normal		Mild		Moderate		Severe

Leading cause of irreversible blindness

Dry Eye Disease

								$2.5 billion core addressable market1
								>11 million US patients diagnosed with
								Meibomian Gland Disease1,2
								Linked to screen time, age
								(postmenopausal women, men 50+),
	Normal		Mild		Moderate		Severe
				systemic medication use
1 Represents Company analysis of third-party estimates. 2 Source: Market Scope 2022 reports.			4

Our Technologies: Efficacy + Intuitive Use

Surgical Glaucoma

Dry Eye

Comprehensive

treatment of

diseased conventional

outflow pathway

Leading Clinical

Trial Results:

ROMEO, GEMINI,

AAO IRIS® Registry

>200K

Cases

performed1

Comprehensive

treatment

of diseased

meibomian glands

Leading Clinical

Trial Results:

SAHARA,

OLYMPIA

>45K

Cases

performed2

1 Based on units of OMNI (and predicates) and SION units shipped as of September 30, 2023. 2 Based on Dry Eye Treatment Lids shipped as of September 30, 2023.

5

Strategic Value Creation Initiatives

Increase OMNI® Utilization

• Maintain and optimize market access
• Train new OMNI surgeons
• Gain share in combination cataract segment
• Continue penetrating standalone MIGS segment
• Expand international markets

TearCare® Access + Acceleration

• Drive market access
• Complete phase 2 of SAHARA RCT
• Expand adoption and usage

6

Primary Open-Angle Glaucoma

POAG is similar to a clog in a kitchen sink: when the eye's natural drainage system (known as the trabeculocanalicular outflow pathway) is blocked and aqueous fluid cannot drain, intraocular pressure (IOP) rises which can cause optic nerve damage and irreversible blindness

1

23

	2	SCHLEMM'S
		CANAL
1		3	DISTAL
	COLLECTOR
		CHANNELS

TRABECULAR

MESHWORK

1. Drain Cover (trabecular meshwork): allows excess aqueous fluid to enter drainage system
2. Sink Pipe (Schlemm's Canal): conducts excess aqueous fluid to exit pathways known as distal collector channels
3. House Plumbing (distal collector channels): leads excess aqueous fluid out of the eye into the venous system

The Trabeculocanalicular Outflow Pathway is an important focal point in treating POAG	7

OMNI: Minimally Invasive + Efficacious Treatment

• Two sequential, ab interno MIGS procedures to help restore natural drainage in the eye
• Up to 360° treatment of all three sources of resistance in trabeculocanalicular outflow pathway

Cannula Tip

Clear Corneal Microincision

2 Schlemm'sCanal

Microcatheter	Trabecular	1
Meshwork

Cannula Tip

Clear Corneal

Microincision

				Collector
Microcatheter				3 Channels

Canaloplasty Using OMNI

expands and dilates 2 Schlemm's Canal And 3 Collector Channels

Trabeculotomy Using OMNI

unroofs the 1 Trabecular Meshwork

OMNI comprehensively treats the trabeculocanalicular outflow pathway	8

OMNI Clinical Highlights

Consistent Efficacy Across Clinical Trials in Standalone and Combination Cataract

IOP (mmHg)

	GEMINI		ROMEO Elevated IOP CC
25.0		(mmHg)	25.0
20.0	23.8	20.0	21.9
15.0	15.4	IOP	15.0	15.1
10.0	10.0

Unmedicated Month 12 (n = 113)	Medicated Month 12 (n = 24)
Baseline (n = 24)
Baseline (n = 113)

Combination Cataract

IOP (mmHg)

ROMEO Elevated IOP SA			TREY Standalone
25.0	21.8	(mmHg)	25.0	21.7
	15.0
20.0			20.0
15.0	15.6	IOP	10.0			15.5
10.0		Medicated	Last Follow-
	Medicated Month 12 (n = 24)				Baseline (n =	Up(n = 22)
	Baseline (n = 24)			22)

Standalone

IOP (mmHg)

Efficacy Demonstrated Out to 2 Years

			ROMEO Two-Year Elevated IOP CC				ROMEO Two-Year Elevated IOP Standalone
25.0									(mmHg)	25.0
20.0	21.7	21.9						20.0	22.1	21.8
15.0				16.1 15.8	14.6 15.3 15.0 15.1	15.6	IOP	15.0				16.7 16.0 16.4 15.9	16.3 15.6	14.7
10.0				10.0
Baseline	M1	M6	M12	Y2		Baseline	M1	M6	M12	Y2
			Consistent Cohort (n = 17)		All ROMEO (n = 24)						Consistent Cohort (n = 17)			All ROMEO (n = 24)

References: GEMINI (Clin Ophthalmol. 2022;16:1225-1234); ROMEO (J Cataract Refract Surg. 2021;47(7):907-915; Ophthalmol Glaucoma. 2021;4(2):173-81); TREY (Int Ophthalmol (2022)); ROMEO 2 Year
(Clin Ophthalmol. 2023:17 1057-1066).	9

OMNI Addresses All Six MIGS POAG Categories

Allows Surgeons to Customize Treatment

$1B	Combination
Cataract MIGS
<15%1 of
Opportunity1	POAG Eyes

$5B	Standalone
MIGS
>85%1 of
Opportunity1	POAG Eyes

Mild Disease

(40%)1

~$0.4B

Opportunity1

~$2B

Opportunity1

Moderate Disease

(40%)1

~$0.4B

Opportunity1

~$2B

Opportunity1

Advanced Disease

(20%)1

~$0.2B

Opportunity1

~$1B

Opportunity1

1 Represents Company analysis of third-party estimates.

10